LIVN vs. HAE, NTUS, MASI, TMDX, ITGR, CNMD, INMD, SLNO, BLFS, and ZYXI
Should you be buying LivaNova stock or one of its competitors? The main competitors of LivaNova include Haemonetics (HAE), Natus Medical (NTUS), Masimo (MASI), TransMedics Group (TMDX), Integer (ITGR), CONMED (CNMD), InMode (INMD), Soleno Therapeutics (SLNO), BioLife Solutions (BLFS), and Zynex (ZYXI). These companies are all part of the "medical" sector.
LivaNova (NASDAQ:LIVN) and Haemonetics (NYSE:HAE) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.
Haemonetics received 4 more outperform votes than LivaNova when rated by MarketBeat users. However, 68.78% of users gave LivaNova an outperform vote while only 60.89% of users gave Haemonetics an outperform vote.
Haemonetics has a net margin of 8.98% compared to LivaNova's net margin of -2.68%. Haemonetics' return on equity of 22.25% beat LivaNova's return on equity.
LivaNova currently has a consensus target price of $66.20, suggesting a potential upside of 8.40%. Haemonetics has a consensus target price of $108.67, suggesting a potential upside of 29.24%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts clearly believe Haemonetics is more favorable than LivaNova.
97.6% of LivaNova shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 0.3% of LivaNova shares are owned by company insiders. Comparatively, 1.8% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Haemonetics had 12 more articles in the media than LivaNova. MarketBeat recorded 15 mentions for Haemonetics and 3 mentions for LivaNova. LivaNova's average media sentiment score of 1.74 beat Haemonetics' score of 0.69 indicating that LivaNova is being referred to more favorably in the media.
Haemonetics has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.
LivaNova has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500.
Summary
Haemonetics beats LivaNova on 14 of the 17 factors compared between the two stocks.
Get LivaNova News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LivaNova Competitors List
Related Companies and Tools
